Harmony Biosciences (HRMY) Tops Q1 EPS by 20c

Harmony Biosciences (NASDAQ: HRMY) reported Q1 EPS of $0.51, $0.20 better than the analyst estimate of $0.31. Revenue for the quarter came in at $85.3 million versus the consensus estimate of $89.61 million.

For earnings history and earnings-related data on Harmony Biosciences (HRMY) click here.

You May Also Be Interested In

• Harmony Biosciences Holdings Inc. (HRMY) PT Lowered to $70 at Oppenheimer
• Evommune, Inc. (EVMN) Misses Q2 EPS by 20c
• SpyGlass Pharma (SGP) Reports Q2 Loss of $0.59